BIOTAGE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 165.5 SEK | +0.49% |
|
+4.42% | +23.78% |
| Apr. 25 | Transcript : Biotage AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Biotage AB Approves a Dividend, Payable on May 3, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.94 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +23.78% | 1.21B | B+ | ||
| -12.91% | 19.08B | A | ||
| -46.21% | 2.65B | C+ | ||
| +18.15% | 1.87B | - | - | |
| -3.12% | 1.61B | - | ||
| -10.69% | 1.02B | - | ||
| -20.89% | 905M | - | C- | |
| -7.14% | 716M | - | ||
| -18.10% | 682M | B+ | ||
| +4.01% | 480M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIOT Stock
- Ratings Biotage AB
